ALZCUR.ST STO
AlzeCure Pharma AB
1W: -8.5%
1M: -15.7%
3M: -3.1%
YTD: +246.5%
1Y: +71.5%
3Y: +50.8%
5Y: -8.7%
kr 6.98 ($0.69)
+0.12 (+1.75%)
Weekly Expected Move ±5.7%
kr 6
kr 6
kr 7
kr 7
kr 8
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
-$1M
-332.8% ▼
Operating Income
-$49M
-35.4% ▼
Net Income
-$48M
-35.3% ▼
EPS (Diluted)
$-0.47
-2.2% ▼
EBITDA
-$48M
-34.7% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $576K | $570K | $476K | $293K | $1M |
| Gross Profit | -$576K | -$570K | -$476K | -$293K | -$1M |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $67M | $46M | $27M | $25M | $36M |
| SG&A Expenses | $11M | $10M | $11M | $11M | $12M |
| Operating Expenses | $78M | $57M | $38M | $36M | $48M |
| Operating Income | -$78M | -$56M | -$38M | -$36M | -$49M |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $1K | $4K | $0 | $0 | $273K |
| Income Before Tax | -$78M | -$56M | -$37M | -$35M | -$48M |
| Tax Expense | $1K | -$203K | $0 | $0 | $18K |
| Net Income | -$78M | -$56M | -$37M | -$35M | -$48M |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-1.98 | $-1.18 | $-0.60 | $-0.46 | $-0.47 |
| EBITDA | -$77M | -$56M | -$38M | -$36M | -$48M |
| Shares Outstanding | 39M | 48M | 62M | 77M | 100M |